NBC Securities Inc. Raises Holdings in GSK plc (NYSE:GSK)

NBC Securities Inc. increased its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 108,287.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,684 shares of the pharmaceutical company's stock after buying an additional 34,652 shares during the quarter. NBC Securities Inc.'s holdings in GSK were worth $1,343,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GSK. Indiana Trust & Investment Management Co grew its stake in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after purchasing an additional 500 shares during the last quarter. Sierra Ocean LLC purchased a new stake in GSK during the 4th quarter valued at about $32,000. Parkside Financial Bank & Trust grew its stake in GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after purchasing an additional 818 shares during the last quarter. Golden State Wealth Management LLC purchased a new stake in GSK during the 4th quarter valued at about $38,000. Finally, Lee Danner & Bass Inc. purchased a new stake in GSK during the 4th quarter valued at about $39,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Price Performance

NYSE:GSK traded up $0.37 during trading hours on Wednesday, hitting $40.83. 2,939,738 shares of the stock were exchanged, compared to its average volume of 4,839,095. GSK plc has a 52-week low of $31.72 and a 52-week high of $44.67. The firm's fifty day moving average price is $37.44 and its 200 day moving average price is $36.25. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a market cap of $84.24 billion, a P/E ratio of 25.68, a P/E/G ratio of 1.12 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. The business's revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.43 earnings per share. As a group, equities research analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a $0.4216 dividend. The ex-dividend date of this dividend is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.13%. GSK's dividend payout ratio is 86.60%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. Hsbc Global Res raised GSK to a "strong sell" rating in a report on Monday, April 28th. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. BNP Paribas initiated coverage on GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.